Evidence map›Paper›PMID 34852834›Full record

ArticleJournal of pharmaceutical health care and sciences2021

A case of improvement of clozapine-induced low leukocyte counts by adenine, cepharanthin and ninjin-yoei-to in a patient with treatment-resistant schizophrenia.

Shintaro Kamei, Ryota Tanaka, Hirofumi Hirakawa, Motoshi Iwao, Rikako Kawanaka, Ryosuke Tatsuta, Takeshi Terao, Hiroki Itoh

Open access · goldAbstract read
In one paragraph

Article in Journal of pharmaceutical health care and sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Shintaro KameiDepartment of Clinical Pharmacy, Oita University Hospital, Yufu-shi, Oita, 879-5593, Japan.
Ryota TanakaDepartment of Clinical Pharmacy, Oita University Hospital, Yufu-shi, Oita, 879-5593, Japan. rtanaka@oita-u.ac.jp.ORCID http://orcid.org/0000-0002-8452-7971
Hirofumi HirakawaDepartment of Neuropsychiatry, Oita University Faculty of Medicine, Yufu-shi, Oita, 879-5593, Japan.
Motoshi IwaoDepartment of Clinical Pharmacy, Oita University Hospital, Yufu-shi, Oita, 879-5593, Japan.
Rikako KawanakaDepartment of Clinical Pharmacy, Oita University Hospital, Yufu-shi, Oita, 879-5593, Japan.
Ryosuke TatsutaDepartment of Clinical Pharmacy, Oita University Hospital, Yufu-shi, Oita, 879-5593, Japan.
Takeshi TeraoDepartment of Neuropsychiatry, Oita University Faculty of Medicine, Yufu-shi, Oita, 879-5593, Japan.
Hiroki ItohDepartment of Clinical Pharmacy, Oita University Hospital, Yufu-shi, Oita, 879-5593, Japan.
Oita University Hospital · JPOita University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough clozapine is the optimal drug for patients with treatment-resistant schizophrenia, the drug has harmful adverse effects such as leukopenia. Adenine and cepharanthine are known to be effective for radiation- or drug-induced leukopenia. Furthermore, ninjin-yoei-to, a Chinese herbal medicine, augments the production of granulocyte-macrophage colony-stimulating factor. Thus, these drugs may be useful for clozapine-induced leukopenia. CASE PRESENTATION: A 21 years-old woman with schizophrenia was hospitalized for initiation of clozapine treatment. Despite concomitant use of adenine, cepharanthine, and lithium carbonate having activities of increasing leukocytes, a decrease in leukocyte counts occurred after the initiation of clozapine. Additional administration of ninjin-yoei-to increased leukocyte counts, which prevented the development of leukopenia.

conclusionsThis is the first case that concomitant use of adenine, cepharanthin, and ninjin-yoei-to exhibited the effectiveness of reversing the decrease in leukocytes caused by clozapine. Monitoring leukocyte counts and preventing leukopenia are essential for successful treatment with clozapine for refractory schizophrenia. These medicines may be a potential option for preventing clozapine-induced leukopenia.

Indexed as

ClozapineLeukopeniaNinjin-yoei-toTreatment-resistant schizophrenia

Identifiers

PMID34852834
PMCPMC8638374
OpenAlexW3215582998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.